The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

March 20, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ajt/shutterstock.com

ajt/shutterstock.com

Recent research analyzed factors influencing the selection of the first-line biologic medications and the real-life factors that lead to switching from those medications to other biologics in treating rheumatoid arthritis (RA). The study compared the use of abatacept and tocilizumab with a tumor necrosis factor alpha inhibitor (TNFi).1,2 Participants were enrolled in the Lombardy Rheumatology Network (LORHEN) after Jan. 1, 2010, and were treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) at eight rheumatology centers in Northern Italy.

You Might Also Like
  • Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients
  • Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention
  • New Developments in Rheumatoid Arthritis Treatment; Personalized Therapy for Patients Ultimate Goal
Explore This Issue
March 2017
Also By This Author
  • FDA Updates Ixekizumab Label to Include Genital Area Psoriasis

The study population (n=1,910) was divided into first- and second-line bDMARD treatment groups, with 1,264 first-line patients (115 received abatacept, 130 received tocilizumab and 1,019 received a TNFi) and 646 second-line patients (143 received abatacept, 97 received tocilizumab and 406 received a TNFi).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A majority of participants initiating bDMARDs received a TNFi. Comorbidities that influenced the choice toward abatacept and tocilizumab compared with a TNFi were categorized by organ system groups: arterial hypertension, cardiovascular disease, diabetes mellitus, dyslipidemia, osteoporosis, peripheral neuropathy, pulmonary disease, thyroid autoimmune disease and other comorbidities not belonging to the prior categories.

In general, older patients were more likely to be prescribed abatacept and tocilizumab compared with patients receiving a TNFi (P<0.0001). A higher prevalence of positive latent tuberculosis infection (LTBI) was associated with abatacept (30%) than with tocilizumab (16%) or TNFi (16%). Combination treatment with methotrexate was lower in tocilizumab-treated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Analysis showed a prevalence of prescribing abatacept in patients who were receiving it as a second-line treatment; were older; had dyslipidemia, pulmonary disease or other comorbidities; and had extra-articular manifestations of RA. Use of tocilizumab was linked to second-line treatment, older age and more severe disease activity. If the first bDMARD was stopped due to an adverse event, this factor influenced a subsequent treatment choice toward abatacept.

In this study, older age and comorbidities influenced changing treatment to abatacept and tocilizumab vs. a TNFi. After patients initially failed first-line treatment with a TNFi, switching to an agent with a different mechanism of action was more widespread.

Insights into Drug-Related Interactions in Older Adults

In a recent cross-sectional study, researchers evaluated the prevalence of possible drug–disease and drug–drug interactions and associated variables in community-dwelling older adults.3 Patients aged 70–79 years (n=3,055) without mobility limitation at their baseline visit in the Health Aging and Body Composition Study were enrolled in this study.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Outcome factors were potential drug–disease and drug–drug interactions identified by using particular criteria from various sources, as well as self-reported nonprescription and prescription drug use. Explicit criteria for 70 potential drug–drug interactions developed by geriatric experts and reactions found to be a cause for drug-related hospitalizations were used.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: biologic therapy, choice, drug, Medication, patient care, physician, Rheumatic Disease, Rheumatoid arthritis, rheumatologist, rheumatologyIssue: March 2017

You Might Also Like:
  • Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients
  • Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention
  • New Developments in Rheumatoid Arthritis Treatment; Personalized Therapy for Patients Ultimate Goal
  • Kidney Problems More Prevalent in Patients with Rheumatoid Arthritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.